PPMD is thrilled to learn of the collaboration of Catabasis and Sarepta Therapeutics, two partners deeply committed to this community. This joint research collaboration will explore the potential combination therapy approach of NF-kB inhibition…Continue
Added by PPMD on September 29, 2016 at 9:21am — No Comments
Sarepta Therapeutics today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping.
Read the announcement from Sarepta:…Continue
Added by PPMD on September 28, 2016 at 6:30pm — No Comments
Santhera Pharmaceuticals today announced that the first patient has been enrolled in Santhera's phase III (SIDEROS) trial. The Phase III SIDEROS trial is designed to confirm the efficacy of Raxone in patients…Continue
Added by PPMD on September 28, 2016 at 8:54am — No Comments
Summit Therapeutics plc today announced it has received Fast Track designation from the US Food and Drug Administration (FDA) for ezutromid in the treatment of…Continue
Hillsdale College announced the creation of a merit-based scholarship to honor the late Ryan Newbanks, a young man who became close to the football program while battling Duchenne muscular dystrophy. The scholarship announcement coincides with the one-year anniversary of Newbanks’ death in 2015, and also with…Continue
Added by PPMD on September 20, 2016 at 9:00am — No Comments
PPMD is excited to see the continued progress of vamorolone (VBP-15), with enrollment in the VISION-DMD Phase 2a Study now beginning. PPMD is proud to be an early funder of vamorolone and are hopeful that this compound will one day prove to be an alternative option for steroids.
Added by PPMD on September 8, 2016 at 1:35pm — No Comments